Does Rallies show 13F holders for MEDP?

Yes. Rallies tracks hedge fund and 13F ownership data for MEDP, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MEDP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MEDP. It does not provide personalized investment advice.

MEDP (Medpace Holdings, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Medpace Holdings, Inc. Common Stock (MEDP) is a publicly traded Healthcare sector company. As of May 21, 2026, MEDP trades at $422.00 with a market cap of $12.01B and a P/E ratio of 25.82. MEDP moved +0.51% today. Year to date, MEDP is -28.11%; over the trailing twelve months it is +37.59%. Its 52-week range spans $250.05 to $628.92. Analyst consensus is buy with an average price target of $447.50. Rallies surfaces MEDP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MEDP stock?

Hedge funds tracked by Rallies that own MEDP include Panagora Asset, Orbimed Advisors, Bridgewater Associates, Maverick Capital, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Medpace Holdings, Inc. Common Stock.

MEDP Key Metrics

Key financial metrics for MEDP
Metric	Value
Price	$422.00
Market Cap	$12.01B
P/E Ratio	25.82
EPS	$16.22
Dividend Yield	0.00%
52-Week High	$628.92
52-Week Low	$250.05
Volume	333.70K
Avg Volume	0
Revenue (TTM)	$2.68B
Net Income	$460.40M
Gross Margin	29.07%

Top Hedge Funds Holding MEDP

Panagora Asset holds 60.03K shares of MEDP, changed +9.81% as of Mar 31, 2026.
Orbimed Advisors holds 44.90K shares of MEDP, changed +0.00% as of Dec 31, 2024.
Bridgewater Associates holds 41.13K shares of MEDP, changed +19.92% as of Mar 31, 2026.
Maverick Capital holds 10.23K shares of MEDP, changed +0.00% as of Mar 31, 2025.
Centerbook Partners holds 3.60K shares of MEDP, changed -42.77% as of Dec 31, 2025.

Latest MEDP News

Medpace climbs as Q1 beat and FY2026 outlook keep buyers active — May 5, 2026
Medpace jumps 4% as traders buy dip after cancellation-driven earnings selloff — Apr 26, 2026
Medpace rebounds after steep post-earnings selloff as investors refocus on Q1 beat — Apr 25, 2026
Medpace rebounds 3% as investors reassess Q1 beat after bookings-driven selloff — Apr 24, 2026
Medpace Q1 Revenue Jumps 26.5% to $706.6M, EBITDA Up 25.9% — Apr 24, 2026

Recent MEDP Insider Trades

GEIGER JESSE J sold 31.71K (~$14.44M) on Mar 17, 2026.
Troendle August J. sold 668 (~$394.58K) on Dec 3, 2025.
Troendle August J. sold 5.70K (~$3.36M) on Dec 2, 2025.

MEDP Analyst Consensus

8 analysts cover MEDP: 0 strong buy, 3 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $447.50.

Common questions about MEDP

Who owns MEDP stock?: Hedge funds tracked by Rallies that own MEDP include Panagora Asset, Orbimed Advisors, Bridgewater Associates, Maverick Capital, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Medpace Holdings, Inc. Common Stock.
Does Rallies show 13F holders for MEDP?: Yes. Rallies tracks hedge fund and 13F ownership data for MEDP, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MEDP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MEDP. It does not provide personalized investment advice.